GlassScriptPhysician profile
Richard A Miller
NPI 1124109319
$327,911.80
in general payments reported to CMS, 2019-2025
37 companies · $7,470 in 2025
The $7,470 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $46K · 2021: $37K · 2022: $54K · 2023: $83K · 2024: $52K · 2025: $7,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $133K · Food and Beverage: $8,097 · Education: $443 · Travel and Lodging: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,350.00 |
| Food and Beverage | $8,097.04 |
| Education | $442.96 |
| Travel and Lodging | $419.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $296,891.43 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,519.08 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $1,874.66 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Actelion Pharmaceuticals US, INC. | $1,177.03 | 2019-2025 | Uptravi, Opsumit |
| Insmed, INC. | $366.23 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $344.79 | 2019-2023 | Yupelri |
| Genzyme Corporation | $282.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $279.27 | 2019-2024 | Dupixent |
| United Therapeutics Corporation | $239.57 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Gilead Sciences, INC. | $215.16 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Sunovion Pharmaceuticals INC. | $192.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $182.98 | 2024-2025 | |
| Genentech USA, INC. | $171.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $162.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $115.79 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $111.37 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $86.90 | 2023-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $86.71 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.64 | 2020-2022 | |
| Pfizer INC. | $55.80 | 2019-2021 | |
| Medtronic, INC. | $50.00 | 2022 | |
| Merck Sharp & Dohme LLC | $48.77 | 2021-2023 | |
| Pulmonx Corporation | $46.22 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Mallinckrodt Enterprises LLC | $42.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.90 | 2020-2021 | |
| Viiv Healthcare Company | $28.50 | 2024 | |
| Allergan, INC. | $28.20 | 2019-2020 | |
| Shire North American Group INC | $27.57 | 2019 | |
| Baxter Healthcare | $22.32 | 2022 | |
| Electromed, INC. | $19.64 | 2024 | Smartvest |
| Shionogi INC | $19.50 | 2025 | Fetroja |
| Resmed Corp | $19.33 | 2019 | |
| Lilly USA, LLC | $18.75 | 2025 | |
| Ani Pharmaceuticals, INC. | $17.15 | 2025 | Purified Cortrophin Gel |
| Fisher & Paykel Healthcare INC | $16.70 | 2021 | |
| Biomerieux INC | $15.99 | 2020 | |
| Mallinckrodt Hospital Products INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.